11:40 AM
Login form
Entries archive

Africa Live News

Main » 2020 » July » 9 » Dr Evidence (DRE), an AI-Enabled SaaS Healthcare Insights Company, Taps Industry Experts Joseph A. Boystak as Chairman of the Board and Amee
11:39 AM
Dr Evidence (DRE), an AI-Enabled SaaS Healthcare Insights Company, Taps Industry Experts Joseph A. Boystak as Chairman of the Board and Amee

 DRE recruits additional expertise for strategic guidance and advice to accelerate adoption of DOC Label™ , DOC Search™ and DOC Analytics™


SANTA MONICA, Calif.-Wednesday 3 June 2020 [ AETOS Wire ]

(BUSINESS WIRE)-- DRE is pleased to welcome Joe Boystak as Chairman of the Board and Ameet Nathwani, MD, as Chairman of its newly formed Medical Strategy Advisory Board (MSAB). These enhancements to the Company reflect the expanded need for keen guidance in this unprecedented time of convergence between expert AI-enabled technology in healthcare and the exponential growth of clinical information. DRE is dedicated to applying sophisticated data science with advanced AI to generate quicker, deeper, more nuanced regulatory-grade scientific and clinical insights for the betterment of patient outcomes.

Boystak is an experienced healthcare venture capitalist and senior healthcare investment banker having been Founding Managing Partner at Health2047 Capital Partners and Founding Managing Director, Global Life Sciences at Jefferies. He is CEO of Brightwaters Capital and is a serial co-founder/investor in biomedical, med tech, health information technology, and artificial intelligence companies with spinouts from UCLA, Johns Hopkins, Harvard/Massachusetts General Hospital, Memorial Sloan Kettering Cancer Center, among others. Boystak is also named co-inventor on 5 issued US/EU patents for first-in-class medical technology developed by Bruin Biometrics LLC, a company he co-founded and was its initial Chairman. He has served on more than a dozen corporate and non-profit boards and currently serves on the Johns Hopkins Bloomberg School of Public Health and Southern California Biomedical Council (SoCalBio) Boards.

“I am honored to join the DRE Board as its Chairman. DRE’s industry leading SaaS platform is facilitating AI-driven drug discovery as pharma and life sciences companies rapidly adopt this technology,” stated Boystak. “Our SaaS platform enables, among others, researchers and drug developers to optimize drug design, improve clinical trial effectiveness, rapidly explore repurposing of compounds, refine FDA label strategies and improve product life cycle management - thus creating substantial ROI for our clients.”

Ameet Nathwani, MD, is Chairman of the newly created MSAB, which will initially consist of five members that represent industry, specialty medical societies, regulatory, data science and patient advocacy. Dr. Nathwani’s most recent position as Executive Vice President, Chief Medical Officer and Chief Digital Officer at Sanofi provides a great framework for the MSAB to inform DRE on strategy, regulatory requirements, research and development, technology and trends in clinical care. The MSAB will also advise on healthcare ecosystem partners for DRE to collaborate with to accelerate treatments and cures.

“It is a privilege to be appointed as the Chairman of the DRE MSAB. At a time when the volume and complexity of scientific data is increasing exponentially, the AI-driven DRE platform provides a state-of-the-art tool which gives healthcare organizations the ability to deconvolute critical scientific data. This agile approach to make rigorous and rapid decisions of real-world data is critical to innovate in this dynamic century of biology,” said Ameet Nathwani, MD. “The MSAB will advise DRE on enhancing the many scientific and healthcare applications of the platform in order to best support a diverse spectrum of partners that will ultimately benefit physicians and patients.”

“With our expanded SaaS platform now including the launch of DOC Analytics™ we are that much closer to achieving our mission of democratizing sophisticated analysis of clinical studies and real-world data for researchers,” added Bob Battista, MBA, FRCPH, FRCP Edin. “We have been fortunate to be backed by a committed group of investors and Board members that Joe will now lead as we chart our next stage of growth. We are similarly privileged to have Dr. Nathwani lead our newly established MSAB. Ameet’s deep sector knowledge and passion for DRE’s SaaS platform provide an incredible basis for guiding our healthcare strategy.”

Joe Boystak and Ameet Nathwani, MD, join a distinguished group of Corporate Board members at DRE that include: Marc Rapaport, immediate past Chairman of DRE, immediate past Chairman of the Board of Cedars-Sinai Medical Center (Los Angeles), private equity investor, and former Executive Vice President and Co-Head of Capital Markets at Drexel Burnham Lambert and Jefferies; Vivek Garipalli, CEO and Co-Founder Clover Health, Co-Founder CarePoint Health, and an active investor in early stage healthcare companies, including founding investor in Flatiron; Ted Meisel, serial healthcare and technology entrepreneur, Executive Founder of AVIA, Executive Chairman of WiserCare, Senior Advisor NextEquity Partners, past Senior Advisor to the Center for Medicare and Medicaid Services (CMS), past President Yahoo Search and past CEO of Overture (acquired by Yahoo); Ananth Bhogaraju, Founder and Managing Director Seven Hills Healthcare Advisors and past Vice Chairman Americas Healthcare Investment Banking Deutsche Bank; Larry Burstein, a healthcare focused Family Office career fund manager; Bob Battista, Co-Founder and CEO DRE, serial healthcare and technology entrepreneur, past Executive Vice President at TheraCom, the first ever specialty pharmacy; and Todd Feinman, MD, Co-Founder and Chief Medical Officer DRE, Hospitalist at Cedars-Sinai Medical Center (Los Angeles) and Director of a large Independent Physician Association.


DRE is a market leading company in the AI-enabled health technology marketplace that deploys state-of-the-art solutions to identify, synthesize, and analyze complex clinical data into actionable insights. DRE provides instant, continuous search and data analysis across critical functions of Pharmaceutical, Biotech, Life Sciences and Medical Technology companies to optimize their clinical programs. Its technology platform provides DRE's customers with a Software-as-a-Service ("SaaS") Insights Engine which empower them to make better decisions from lab to patient.


Chris Yu
+1 (310) 595-1265

Permalink :

Views: 61 | Added by: africa-live | Rating: 0.0/0
Total comments: 0